OpGen (Nasdaq:OPGN) - Stock Price, News & Analysis

OPGN Stock Overview

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally.

About the company

OPGN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Risk Analysis

Does not have a meaningful market cap ($8M)

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months

Earnings have declined by 22.6% per year over past 5 years

+ 1 more risk

OpGen, Inc. Competitors

Fresh2 Group

NasdaqCM:FRES

US$7.8m

Trevena

NasdaqCM:TRVN

US$7.4m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Vaccinex

NasdaqCM:VCNX

US$7.7m

Price History & Performance

Summary of all time highs, changes and price drops for OpGen
Historical stock prices
Current Share Price	US$0.60
52 Week High	US$3.84
52 Week Low	US$0.17
Beta	-0.69
1 Month Change	23.69%
3 Month Change	130.07%
1 Year Change	-45.46%
3 Year Change	-98.74%
5 Year Change	-99.72%
Change since IPO	-100.00%

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

Shareholder Returns

	OPGN	US Biotechs	US Market
7D	-14.3%	-4.2%	-3.7%
1Y	-45.5%	-2.0%	20.5%

Return vs Industry: OPGN underperformed the US Biotechs industry which returned -1.7% over the past year.

Return vs Market: OPGN underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is OPGN's price volatile compared to industry and market?
OPGN volatility
OPGN Average Weekly Movement	22.8%
Biotechs Industry Average Movement	11.5%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.0%

Stable Share Price: OPGN's share price has been volatile over the past 3 months.

Volatility Over Time: OPGN's weekly volatility has decreased from 33% to 23% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2001	93	David Lazar	www.opgen.com

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company’s products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers.

OpGen, Inc. Fundamentals Summary

How do OpGen's earnings and revenue compare to its market cap?
OPGN fundamental statistics
Market cap	US$7.74m
Earnings (TTM)	-US$26.16m
Revenue (TTM)	US$3.07m

2.3x

P/S Ratio

-0.3x

P/E Ratio

Is OPGN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OPGN income statement (TTM)
Revenue	US$3.07m
Cost of Revenue	US$10.77m
Gross Profit	-US$7.70m
Other Expenses	US$18.46m
Earnings	-US$26.16m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-2.18
Gross Margin	-250.95%
Net Profit Margin	-852.12%
Debt/Equity Ratio	343.7%

How did OPGN perform over the long term?

See historical performance and comparison

OPGN Stock Overview

Rewards

Risk Analysis

OpGen, Inc. Competitors

NasdaqCM:FRES

US$7.8m

NasdaqCM:TRVN

US$7.4m

NasdaqCM:VBLT

US$12.1m

NasdaqCM:VCNX

US$7.7m

Price History & Performance

Recent News & Updates

OpGen, Inc. announced delayed annual 10-K filing

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Recent updates

OpGen, Inc. announced delayed annual 10-K filing

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. announced that it expects to receive $1 million in funding

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

OpGen to raise $3.38M in direct stock offering

OpGen's subsidiary signs R&D agreement with FIND

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen launches sequencing services for infectious diseases in US

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen reports preliminary revenue estimate for Q2 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen gains on insider buying

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

OpGen, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders

OpGen, Inc., Annual General Meeting, Jun 09, 2021

OpGen reports prelim Q4 & FY20 revenue

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

OpGen, Inc. Announces Results from 1,400 Patient Sample Multicenter Study Published: Unyvero LRT BAL Panel Provides Accurate Detection in Bronchoalveolar Lavage Fluid, Allowing Enhanced Diagnosis of Lower Respiratory Tract Infections

OpGen, Inc. announced that it expects to receive $10 million in funding

OpGen launches $10M private placement

OpGen EPS misses by $0.04, beats on revenue

OpGen, Inc. to Report Q3, 2020 Results on Nov 11, 2020

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

OpGen, Inc. Demonstrates the Clinical Utility of Unyvero LRT Panel and Its Potential Impact on Antibiotic Use in Hospitalized Patients with Suspected Pneumonia

OpGen, Inc. Announces Successful Completion of Study Collaboration with Karolinska Institutet on Bacterial Co-Infections in Covid-19 Pneumonia Patients and Presents Data on Unyvero Hpn Panel At Eccvid 2020